Creo Medical Group PLC (1RC.SG)

0,3800 0,0000 (0,00%) Börsenschluss: 04:31PM CEST

Creo Medical Group PLC

Creo House
Unit 2, Beaufort Park Beaufort Park Way
Chepstow NP16 5UH
United Kingdom
44 12 9160 6005
https://creomedical.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 279

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Craig Jonathan Gulliford	CEO & Executive Director	549,15k	N/A	1970
Prof. Christopher Paul Hancock	Founder, CTO & Executive Director	418,46k	N/A	1967
Mr. Richard John Rees ACA	CFO, Company Secretary & Executive Director	418,03k	N/A	1976
Mr. David Gerard Woods	Chief Commercial Officer & Executive Director	518,62k	N/A	1965
Mr. Phil Hales	Sales & Marketing Director	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for flexible endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device designed for soft tissue ablation; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the GI tract; ScopeClip, a single-use rotational and repositionable hemoclips; ScopeBite, a portfolio of biopsy forceps; ScopeGrasp, a portfolio of grasping forceps; and ScopeInject, an injection needle. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.

Corporate Governance

Creo Medical Group PLCs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.